Compare AbbVie Inc (ABBV) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI South Africa ETF — how do they compare? AbbVie Inc trades at $248 (market cap $438.19B), while iShares MSCI South Africa ETF trades at $68.36. The key difference: AbbVie Inc pays a 2.79% dividend while iShares MSCI South Africa ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | EZA | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $263.58 | $81.60 |
52-Week Low | $197.38 | $56.36 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.47, up 0.99% with a bullish technical signal supported by moving averages and oversold RSI levels. The company demonstrates strong revenue growth with 2025 revenue reaching $61.16B and consistent earnings beats in recent quarters. Recent positive clinical trial results for ovarian cancer treatment and institutional accumulation signal confidence in the company's pipeline and growth trajectory.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 consensus price target offering 13% upside. Key risks include patent cliffs in the 2030s and high debt levels, but robust immunology portfolio growth and dividend aristocrat status provide stability. The stock's current valuation metrics suggest premium pricing relative to historical levels.
EZA trades at $69.65, up 4.14% today, with a bullish technical signal from moving averages but overbought oscillators. The stock faces resistance near $68 and support at $66. Recent news highlights macroeconomic pressures on its South African-focused portfolio, including exposure to gold, banking, and platinum group metals amid rising interest rates and inflation.
The outlook is mixed, with technical strength offset by fundamental headwinds from global reflation. Investment opportunities hinge on commodity price stability, while risks include yield curve dynamics and cost of capital increases that may pressure constituent earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
